Scott Myers, Chairman and Chief Executive Officer
Scott Myers has served as our President and Chairman and Chief Executive Officer since June 2018 and September 2018 respectively. Prior to joining Rainier Therapeutics Scott Myers has more than 20 years of biopharmaceutical industry experience in product development, commercialization and corporate transactions. He was most recently CEO, President and a Director of Seattle-based Cascadian Therapeutics (CASC), an oncology company, until it was acquired by Seattle Genetics in March of 2018. Prior to Cascadian, he was CEO of Aerocrine AB (AERO), a medical device company based in Stockholm, Sweden, and Morrisville, NC, until it was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Scott held senior commercial operations, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson. From 2012-2014, Scott was an independent director of Orexo, AB (OREX), a Swedish CNS company. Currently, Scott is an Independent Director and member of the Audit Committee for Harpoon Therapeutics (HARP), a publicly traded Oncology Company focusing on innovative T Cell engaging platforms. Scott is also an Independent Director and member of the Nomination and Governance committee of SelectaBio (SELB), SelectaBio has developed the ImmTOR platform focused on the treatment of Gout and other novel therapies for immune system diseases. Scott earned his BA in biology from Northwestern University and his MBA from The University of Chicago Booth School of Business.
Steve Abella, MD, Chief Medical Officer
Esteban (Steve) Abella has been actively involved in cancer clinical trials research for nearly 30 years including over 8 years in pharmaceutical industry, most recently at Gilead Sciences. At Gilead, Steve was a Senior Director leading the Non-Hodgkin’s lymphoma and leukemia efforts, as well as serving as a core member of the oncology senior leadership team. Prior to that he served as Executive Director at Amgen predominately responsible for the white cell franchise (Neulasta/Neupogen) global development efforts across clinical research and medical affairs. His clinical experiences over the 23 years prior joining industry, span 15 years in academic oncology, serving as a Professor of Pediatric, Oncology, and Medicine at the Barbara Ann Karmanos Cancer institute predominately focused in stem cell transplantation and oncology clinical trials. Subsequently, he focused on developing and serving as the initial group president for a large multispecialty private practice group in Arizona of over 60 physicians. Steve completed his fellowship and residency training at Wayne State University School of Medicine after graduating with a degree in medicine from the Universidad Central del Este. He attended the University of Pennsylvania for undergraduate studies.
Graeme Currie, Ph.D., Chief Operating Officer
Graeme Currie was most recently Vice President of Clinical Science and Operations at Dynavax Technologies Ltd. Graeme joined Dynavax in April 2016 and was a part of the team working towards approval of HEPLISAV-B and progressing the Immuno-oncology portfolio. Prior to that he spent six years at Regeneron Pharmaceuticals with the title Vice President of Clinical Project Management and Operations and oversaw all therapeutic areas, spanning 16 molecules and multiple therapeutic areas. Prior to Regeneron, Graeme was Vice President of Clinical Operations at Sepracor in Boston and at PDL Biopharma in the Bay Area. Graeme also spent 6 years as a Director at Gilead sciences working in Hepatitis and played a significant role in developing Hepsera for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN and Glaxo Welcome, based in London and ran global programs for the development of Lanreotide for the treatment of Acromegaly and Valtrex for the treatment of HSV. Graeme received a BSc from the University of Salford in England and a PhD in Oncology from Aston University, Birmingham, England.
Julie Eastland, Chief Financial Officer and Chief Business Officer
Julie Eastland most recently served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, from September 2010 to May 2018, having helped negotiate the sale of the company to Seattle Genetics and then assisted in the subsequent transition. From 2006 to 2010, she was the Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company. Prior to VLST, Julie held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen. She is currently a Director of Pascal Biosciences, a publicly listed biotechnology company on the Toronto Venture Exchange, and Harpoon Therapeutics, a public immune-oncology company. She received an MBA from Edinburgh University Management School and a BS in finance from Colorado State University.
Gary Christianson, Chief Technical Officer
Gary Christianson most recently served as Chief Operating Officer at Nohla Therapeutics. Prior to that, he served as Chief Operating Officer at Cascadian Therapeutics since 2007. Cascadian Therapeutics was acquired by Seattle Genetics in March 2018. Prior to his role at Cascadian, Mr. Christianson served as the site director for GlaxoSmithKline’s Biologics Unit following its acquisition of Corixa Corp. From 1999 to 2005, Mr. Christianson held positions as vice president, technical operations and general manager overseeing manufacturing and commercial product development. Prior to Corixa, Mr. Christianson served for 12 years overseeing manufacturing and site operations at RIBI ImmunoChem Research, a biopharmaceutical company developing late-stage adjuvant technology. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University.
Valerie Fauvelle, Vice President, Regulatory Affairs
Valerie Fauvelle has more than 18 years of Regulatory Affairs experience in drug development. Prior to BioClin Therapeutics, Ms. Fauvelle worked at Cascadian Therapeutics, most recently as Senior Director, Regulatory Affairs, with primary responsibility for INDs and international submissions for treatments of multiple cancers. During her 8 years with Cascadian Therapeutics, she played a key role in the strategic development of the pivotal program for HER2+ breast cancer. Prior to Cascadian Therapeutics, she held positions with Gilead Sciences, ICOS, and Seattle Genetics, working on both biologics and small molecules targeting cancer, urology, respiratory and cardiovascular indications. She holds a BA in psychology from the University of Washington and a MSc in Health Sciences from The George Washington University School of Medicine. In addition, she has a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society.